Formula Pharmaceuticals, Inc. is a privately-held biopharmaceutical company developing a proprietary, next generation Chimeric Antigen Receptor (CAR) immunotherapy platform. Formula’s technology platform offers important opportunities for improvements to existing CAR approaches, with the objective to significantly increase patient access, clinical benefit potential, and cost-effectiveness of manufacturing.